CClinicalTrials.gg
RecruitingNCT04701047Updated Jan 15, 2025

Prospective Observational Prolapse Study

An observational study in Vaginal Prolapse, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by University Hospital, Ghent · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Female
01

Study summary

The rationale of the study is to investigate the results of a prolapse treatment in adult women with a vaginal prolapse. The investigators will investigate this by taking questionnaires in women undergoing a surgical prolapse repair and in women that are being treated by a vaginal pessary. The objective is to compare the results of the different methods with each other and to observe the evolution of the symptoms in patients undergoing surgery or pessary use. The investigators would also like to discover existing problems in pessary use and adverse effects.

Read the detailed description

The rationale of the study is to investigate the results of a prolapse treatment in adult women with a vaginal prolapse. The investigators will investigate this by taking questionnaires in women undergoing a surgical prolapse repair and in women that are being treated by a vaginal pessary. The objective is to compare the results of the different methods with each other and to observe the evolution of the symptoms in patients undergoing surgery or pessary use. The investigators would also like to discover existing problems in pessary use and adverse effects.

The questionnaires that will be used are the PFDI-20 (pelvic floor distress inventory), PFIQ-7 (pelvic floor impact questionnaire), PISQ-9 (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire) and a custom-made questionnaire to further investigate the behavior towards pessary use of our patients and the adverse effects they are dealing with. The questionnaires will be taken before the treatment has started, 6 weeks post treatment start, one-year post treatment start, two years post treatment start and 5 years post treatment start. A POP-Q (Pelvic Organ Prolapse Quantification) investigation will be performed to estimate the degree of vaginal prolapse before the start of the treatment. Since clinical follow up is not necessarily needed after one year for the women who undergo surgery, their questionnaires will be taken via telephone or e-mail. For women that are being treated with pessaries the investigators will also take our custom-made questionnaire at 4 and 8 months after starting the treatment.

The investigators would like to recruit 100 women for this study, older than 18 years old who have not undergone a previous treatment with a pessary or surgery for vaginal prolapse. Another exclusion criterium are women who still have a child wish and women who have contraindications for surgery. The investigators will also exclude women who don't speak Dutch or women who cannot give a written consent.

The investigators hypothesize that woman being treated with one year of pessary use are overall not having more symptoms than woman that underwent a surgery. The investigators hypothesize that woman being treated with five years of pessary use are overall having less symptoms than woman that underwent a surgery.

02

Conditions studied

  • Vaginal Prolapse
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The research population will include women above the age of 18 years old who consult the department of urology or the department of gynaecology at the university hospital of Ghent with symptoms of vaginal prolapse. The patients will be recruited by their attending physician. There will be no exclusion on the degree of vaginal prolapse. All symptomatic prolapses will be included in this study. Exclusion criteria will be having undergone a previous treatment with a pessary or surgery for vaginal prolapse, contraindications for surgery or pessary use, active of passive child wish, not able to understand the Dutch language and not able to give a written consent.

Inclusion criteria

  • women with a symptomatic vaginal prolapse
  • older than 18 years

Exclusion criteria

Exclusion Criteria:

  • under 18 years old
  • undergone a previous treatment with a pessary or surgery for vaginal prolapse
  • contra-indications for surgery or pessary use
  • active or passive child wish
  • not able to understand the Dutch language
  • not able to give a written consent
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • pessary

    Vaginal prolapse being treated by pessary

    Device: vaginal pessary

  • surgery

    Vaginal prolapse being treated by surgical repair

    Procedure: Vaginal prolapse surgery

Interventions

  • Devicevaginal pessary

    insertion and follow up of a vaginal pessary

  • ProcedureVaginal prolapse surgery

    surgery and follow up after vaginal prolapse surgery

05

What researchers measure

Primary outcomes

  1. Change in Pelvic Floor Disability Index (PFDI-20)

    Change in scores on the short-form version of the Pelvic Floor Distress Inventory (PFDI). It is a health-related quality of life questionnaire for women with pelvic floor conditions to fill out.

    Time frame: Baseline, 6 weeks, one year, two years, five years

  2. Change in pelvic floor impact questionnaire (PFIQ-7)

    Change in scores on the shortened version of the Pelvic Floor Impact Questionnaire (PFIQ). It is a health-related quality of life questionnaire for women with pelvic floor conditions to fill out.

    Time frame: Baseline, 6 weeks, one year, two years, five years

  3. Change in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)

    Change in scores on the short form of the PISQ-31 that evaluates sexual function in women with urinary incontinence and/or pelvic organ prolapse

    Time frame: Baseline, 6 weeks, one year, two years, five years

Secondary outcomes

  1. Subjective self-reported satisfaction scores for pessary use as measured via a custom-made Likert scale questionnaire

    Study participants are asked how satisfied they are with their pessary use at 4 months after the initiation of pessary use. Participants can choose one of five graded answers on the Likert scale: 5 Very satisfied 4 satisfied 3 neutral 2 unsatisfied 1 very unsatisfied

    Time frame: 4 months after start of therapy

  2. Subjective self-reported satisfaction scores for pessary use as measured via a custom-made Likert scale questionnaire

    Study participants are asked how satisfied they are with their pessary use at 8 months after the initiation of pessary use. Participants can choose one of five graded answers on the Likert scale: 5 Very satisfied 4 satisfied 3 neutral 2 unsatisfied 1 very unsatisfied

    Time frame: 8 months after start of therapy

  3. Self-reported behavior and patient preferences towards pessary use via a custom-made questionnaire

    frequency of pessary use, subjective reasons why not to wear a pessary and alternative treatment considerations as assessed by open-ended and yes or no type questions

    Time frame: 4 months after initiation of therapy

  4. Self-reported behavior and patient preferences towards pessary use via a custom-made questionnaire

    frequency of pessary use, subjective reasons why not to wear a pessary and alternative treatment considerations as assessed by open-ended and yes or no type questions

    Time frame: 8 months after initiation of therapy

  5. Subjective self-reported adverse effects of pessary use as measured via a custom-made questionnaire

    Participants will be asked if they experienced side effects that they feel has been caused by pessary use via a custom-made questionnaire: The most commonly anticipated answers have been listed with the option of patients describing other potential adverse events (shown below): * No side effects * It feels uncomfortable * It gives an itchy/burning sensation * More vaginal discharge * Other..........

    Time frame: 4 months after initiation of therapy

  6. Subjective self-reported adverse effects of pessary use as measured via a custom-made questionnaire

    Participants will be asked if they experienced side effects that they feel has been caused by pessary use via a custom-made questionnaire: The most commonly anticipated answers have been listed with the option of patients describing other potential adverse events (shown below): * No side effects * It feels uncomfortable * It gives an itchy/burning sensation * More vaginal discharge * Other..........

    Time frame: 8 months after initiation of therapy

Other outcomes

  1. Amount of pessaries tried before current pessary

    Number of pessaries that are being fitted before finding a suitable one via a custom made questionnaire.

    Time frame: 4 months after initiation of therapy

  2. Amount of pessaries tried before current pessary

    Number of pessaries that are being fitted before finding a suitable one via a custom made questionnaire.

    Time frame: 8 months after initiation of therapy

  3. Duration of the pessary consultation

    Duration of a pessary consultation in minutes.

    Time frame: 4 months after initiation of therapy

  4. Duration of the pessary consultation

    Duration of a pessary consultation in minutes.

    Time frame: 8 months after initiation of therapy

06

Study locations

1 of 1 sites recruiting
  • Ghent University Hospital
    Ghent, 9000, Belgium
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04701047
Lead sponsor
University Hospital, Ghent
Responsible party
Sponsor
First posted
Jan 8, 2021
Start date
Sep 3, 2021
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jan 15, 2025

Study contacts

Kessewa Abosi-Appeadu
Contact
kessewa.abosiappeadu@ugent.be
+32 9 332 3774
Steffi Van Wessel
Contact
steffi.vanwessel@ugent.be
+32 9 332 0289
Tjalina Hamerlynck
principal investigator · UZ Gent
Steven Weyers
principal investigator · UZ Gent
Van Wessel Steffi
study director · UZ Gent
Abosi Appeadu Kessewa
study chair · UZ Gent
Decalf Veerle
study chair · UZ Gent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion